All In Biotech

Drug Trial Radar · NCT03165734

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 407 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

407

Actual

Start

Jun 26, 2017

Primary completion

Oct 5, 2026

Study completion Oct 13, 2028

Sponsor

Lead sponsor
Swedish Orphan BiovitrumIndustry
Sponsor type
Industry
Collaborators
PSI CRO
First posted
May 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib

Conditions

  • Primary Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis

Interventions

  • PacritinibDrug

    Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base

  • Physician's Choice medicationsDrug

    Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Spleen volumeTime frame: From baseline at 24 weeks
  2. Total Symptom Score (TSS) (excluding tiredness)Time frame: From baseline at Week 24

Locations

207 sites in 24 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center

    Birmingham, Alabama

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA David Geffen School of Medicine

    Los Angeles, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • Rocky Mountain Cancer Centers (US Oncology/McKesson)

    Boulder, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • George Washington University-Medical Faculty Associates

    Washington D.C., District of Columbia

  • Cleveland Clinic Florida

    Weston, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • University of Kansas Cancer Center and Medical Pavilion

    Westwood, Kansas

  • Ochsner Medical Center

    New Orleans, Louisiana

  • Saint Agnes Hospital

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Regional Cancer Care Associates LLC - CCBD Division

    Bethesda, Maryland

  • Maryland Oncology Hematology, PA- Columbia

    Columbia, Maryland

  • Michigan Medicine Hematology Clinic-Rogel Cancer Center

    Ann Arbor, Michigan

  • Cancer and Hematology Centers of Western Michigan

    Grand Rapids, Michigan

  • Washington University School of Medicine-Siteman Cancer Center

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada- Twain Office

    Las Vegas, Nevada

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Medical Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Memorial Sloan -Kettering Cancer Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • Duke University Hospital

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • The James Cancer Hospital and Solove Research Institute

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • The Sarah Cannon Research Institute-Tennessee Oncology

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Mays Cancer Center

    San Antonio, Texas

  • Texas Oncology- San Antonio

    San Antonio, Texas

Showing 40 of 207 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.